CAPTRUST Financial Advisors
IMVT icon

CAPTRUST Financial Advisors’s Immunovant IMVT Stock Holding History

CAPTRUST Financial Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,792
Closed -$455K – 2393
2023
Q4 		$455K Buy
+10,792
New +$397K ﹤0.01% 1800
2022
Q2 		– Sell
-100
Closed -$1K – 5029
2022
Q1 		$1K Sell
100
-570
-85% -$3.55K ﹤0.01% 4702
2021
Q4 		$6K Buy
+670
New +$5.53K ﹤0.01% 3987
2021
Q3 		– Sell
-351
Closed -$4K – 4697
2021
Q2 		$4K Buy
+351
New +$4.9K ﹤0.01% 3947

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

CAPTRUST Financial Advisors's IMVT Position: Q1 2024 in Review

CAPTRUST Financial Advisors sold out of Immunovant (IMVT) in Q1 2024, closing a stake of 10,792 shares — an estimated $455K sold.

CAPTRUST Financial Advisors first reported a position in IMVT in Q2 2021 and held it in 4 quarters. The position peaked at $455K in Q4 2023. 209 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

  • CAPTRUST Financial Advisors reported no remaining Immunovant position as of Q1 2024 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 10,792 Immunovant shares in Q1 2024, an estimated $455K.
  • CAPTRUST Financial Advisors first reported a position in Immunovant in Q2 2021 and held it in 4 quarters.
  • CAPTRUST Financial Advisors's Immunovant position peaked at $455K in Q4 2023.
  • 209 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2024, filed 15 May 2024.